Cardiac Science Announces Third Quart...((26151) -22.8% 11320 7.3% In...),Health

Date:11/9/2009

(26,151) -22.8% 11,320 7.3% Income tax expense (42,563) -37.1% (4,245) -2.7% ------- ----- ------ ---- Net income (loss) (68,714) -59.9% 7,075 4.6% Less: Net income attributable to noncontrolling interests (476) -0.4% (257) -0.2% ---- ---- ---- ---- Net income (loss) attributable to Cardiac Science Corporation $(69,190) -60.3% $6,818 4.4% ======== ===== ====== === Net income (loss) per share attributable to Cardiac Science Corporation: Basic $(2.98) $0.30 Diluted $(2.98) $0.29 Weighted average shares outstanding: Basic 23,209,181 22,840,524 Diluted 23,209,181 23,402,011 Cardiac Science Corporation and Subsidiaries Condensed Consolidated Balance Sheets (unaudited) (in thousands) September December 30, 31, 2009 2008 --------- -------- ASSETS Current Assets: Cash and cash equivalents $31,628 $34,655 Accounts receivable, net 28,387 31,665 Inventories 26,011 24,692 Deferred income taxes - 8,366 Prepaid expenses and other current assets 2,763 3,144 ----- ----- To
'/>"/>

SOURCE Cardiac Science Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery